Skip to Main Content

Sarepta Therapeutics is in more trouble.

The Japanese drugmaker NS Pharma said Wednesday that the paperwork required to seek approval for a new drug to treat Duchenne muscular dystrophy was submitted to the U.S. Food and Drug Administration.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!